Janux Therapeutics (JANX) Accumulated Depreciation & Amortization: 2020-2025
Historic Accumulated Depreciation & Amortization for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $6.5 million.
- Janux Therapeutics' Accumulated Depreciation & Amortization rose 46.28% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.9 million, marking a year-over-year increase of 55.62%. This contributed to the annual value of $5.0 million for FY2024, which is 69.94% up from last year.
- Per Janux Therapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $6.5 million for Q3 2025, which was up 8.10% from $6.0 million recorded in Q2 2025.
- Janux Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $6.5 million for Q3 2025, and its period low was $39,000 during Q2 2021.
- Its 3-year average for Accumulated Depreciation & Amortization is $3.9 million, with a median of $3.9 million in 2024.
- Data for Janux Therapeutics' Accumulated Depreciation & Amortization shows a peak YoY spiked of 759.09% (in 2022) over the last 5 years.
- Quarterly analysis of 5 years shows Janux Therapeutics' Accumulated Depreciation & Amortization stood at $131,000 in 2021, then spiked by 641.98% to $972,000 in 2022, then surged by 199.79% to $2.9 million in 2023, then spiked by 69.94% to $5.0 million in 2024, then spiked by 46.28% to $6.5 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $6.5 million for Q3 2025, versus $6.0 million for Q2 2025 and $5.5 million for Q1 2025.